Payment overview · 2025
General Payments
$27.60
1 reported records · 1 companies
Healthcare provider profile · identity verified
Hitendrakumar M Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MICHIGAN CITY, IN · NPI 1407946486
Verified facts
What the public records show
CMS Open Payments records show Hitendrakumar M Patel, MD received $27.60 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.60 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $27.60 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $27.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1005 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 692 | 183 |
| Lisinopril | Lisinopril | 469 | 119 |
| Metformin Hcl | Metformin Hcl | 398 | 97 |
| Potassium Chloride | Potassium Chloride | 364 | 66 |
| Gabapentin | Gabapentin | 362 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 75 |
| Furosemide | Furosemide | 352 | 90 |
| Omeprazole | Omeprazole | 352 | 85 |
| Donepezil Hcl | Donepezil Hcl | 279 | 47 |
| Memantine Hcl | Memantine Hcl | 253 | 38 |
| Carvedilol | Carvedilol | 247 | 66 |
| Eliquis | Apixaban | 239 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 60 |
| Alprazolam | Alprazolam | 209 | 49 |
| Losartan Potassium | Losartan Potassium | 205 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 190 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 43 |
| Glimepiride | Glimepiride | 155 | 34 |
| Sertraline Hcl | Sertraline Hcl | 143 | 39 |
| Prednisone | Prednisone | 128 | 81 |
| Simvastatin | Simvastatin | 128 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 22 |
| Allopurinol | Allopurinol | 107 | 31 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 106 | suppressed |
| Januvia | Sitagliptin Phosphate | 103 | 16 |
| Atenolol | Atenolol | 102 | 28 |
| Ozempic | Semaglutide | 98 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 20 |
| Mirtazapine | Mirtazapine | 94 | 26 |
| Cefdinir | Cefdinir | 92 | 71 |
| Meloxicam | Meloxicam | 92 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 33 |
| Levetiracetam | Levetiracetam | 90 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 19 |
| Xarelto | Rivaroxaban | 89 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 88 | 24 |
| Trazodone Hcl | Trazodone Hcl | 85 | 22 |
| Alendronate Sodium | Alendronate Sodium | 83 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 30 |
| Spironolactone | Spironolactone | 78 | 24 |
| Buspirone Hcl | Buspirone Hcl | 74 | 23 |
| Finasteride | Finasteride | 73 | 18 |
| Montelukast Sodium | Montelukast Sodium | 73 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 22 |
| Azithromycin | Azithromycin | 71 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 71 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 17 |
| Jardiance | Empagliflozin | 65 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 63 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 45 |
| Lorazepam | Lorazepam | 60 | 13 |
| Famotidine | Famotidine | 59 | 25 |
| Clonazepam | Clonazepam | 57 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 16 |
| Ezetimibe | Ezetimibe | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 16 |
| Cephalexin | Cephalexin | 54 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Pregabalin | Pregabalin | 52 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 51 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 49 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Ibuprofen | Ibuprofen | 47 | 11 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 44 | 21 |
| Risperidone | Risperidone | 41 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Baclofen | Baclofen | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 13 |
| Glipizide | Glipizide | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Valsartan | Valsartan | 37 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 34 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 13 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Klor-Con M10 | Potassium Chloride | 30 | 11 |
| Methimazole | Methimazole | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 21 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 25 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Scopolamine | Scopolamine | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 15 |
| Metolazone | Metolazone | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mesalamine | Mesalamine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.60 · 1 records | ABBVIE INC. | AVYCAZ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error